THC Farmaceuticals, Inc. (CBDG)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -25 Thousand USD | -105.82% |
| 2022 | 429.86 Thousand USD | 2649.64% |
| 2021 | -15.85 Thousand USD | 46.9% |
| 2020 | -119.69 Thousand USD | 79.8% |
| 2019 | -994.18 Thousand USD | -999.65% |
| 2018 | -14.29 Thousand USD | -113.28% |
| 2017 | -6695.00 USD | 95.06% |
| 2016 | -135.51 Thousand USD | 0.0% |
| 2014 | -23.41 Thousand USD | -26.33% |
| 2013 | -18.53 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 Q3 | -5370.00 USD | 48.02% |
| 2022 Q1 | -740.00 USD | 0.0% |
| 2022 Q2 | -10.33 Thousand USD | -1295.95% |
| 2021 FY | - USD | 46.9% |
| 2020 FY | - USD | 79.8% |
| 2020 Q1 | -9440.00 USD | 0.0% |
| 2019 Q3 | -48.57 Thousand USD | -16.28% |
| 2019 FY | - USD | -999.65% |
| 2019 Q2 | -41.77 Thousand USD | 0.0% |
| 2018 FY | - USD | -113.28% |
| 2017 FY | - USD | 95.06% |
| 2016 FY | - USD | 0.0% |
| 2015 Q2 | -19.38 USD | -131.69% |
| 2015 Q1 | -8.36 USD | -26.56% |
| 2015 Q3 | -35.23 USD | -81.84% |
| 2014 Q2 | -1.86 USD | 85.27% |
| 2014 Q1 | -12.61 USD | -317.96% |
| 2014 FY | - USD | -26.33% |
| 2014 Q4 | -6.61 USD | -182.76% |
| 2014 Q3 | -2.34 USD | -25.78% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | -1.30 USD | 0.0% |
| 2013 Q3 | -3.75 USD | -188.91% |
| 2013 Q4 | -3.02 USD | 19.58% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.965% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.578% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.961% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.856% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.027% |
| Mesoblast Limited | -62.38 Million USD | 99.96% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 98.372% |
| Genus plc | 73.7 Million USD | 100.034% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.622% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 99.295% |
| Marizyme, Inc. | -34.28 Million USD | 99.927% |
| ContraFect Corporation | -64.99 Million USD | 99.962% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.715% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.448% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 98.217% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 99.055% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 98.924% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 95.174% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.333% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.948% |
| EV Biologics, Inc. | -1.26 Million USD | 98.027% |
| Q BioMed Inc. | -617.62 Thousand USD | 95.952% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.7% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 96.047% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 98.906% |
| Biomind Labs Inc. | -1.03 Million USD | 97.583% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.253% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.651% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.815% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 98.319% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 99.356% |
| IMV Inc. | -35.52 Million USD | 99.93% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.842% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 99.001% |
| GB Sciences, Inc. | -1.41 Million USD | 98.239% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.742% |
| HST Global, Inc. | -5303.00 USD | -371.431% |
| CSL Limited | 4.78 Billion USD | 100.001% |
| Halberd Corporation | -74.27 Thousand USD | 66.343% |
| Enzolytics Inc. | -2.12 Million USD | 98.822% |
| Resverlogix Corp. | -11.74 Million USD | 99.787% |
| Affymax, Inc. | -14.29 Million USD | 99.825% |
| SYBLEU INC | -141.57 Thousand USD | 82.341% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 99.184% |
| argenx SE | -216.02 Million USD | 99.988% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.955% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 102.054% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 98.332% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 106.599% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.591% |
| Zenith Capital Corp. | -8.6 Million USD | 99.71% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.99% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -43.505% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 98.978% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 85.797% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.937% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 99.136% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 97.611% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 471.802% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 98.571% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 98.699% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.669% |
| ONE Bio Corp. | 13.61 Million USD | 100.184% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 86.195% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 98.785% |
| Agentix Corp. | -1.37 Million USD | 98.178% |
| LadRx Corporation | 412.28 Thousand USD | 106.064% |
| Cell Source, Inc. | -4.27 Million USD | 99.415% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 93.192% |
| Regen BioPharma, Inc. | 1.46 Million USD | 101.705% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 97.332% |
| NovAccess Global Inc. | -1.03 Million USD | 97.584% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.282% |
| Itoco Inc. | -1.86 Million USD | 98.662% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 93.414% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 97.76% |
| Kadimastem Ltd | -2.62 Million USD | 99.047% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 89.546% |
| CytoDyn Inc. | -18.02 Million USD | 99.861% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 68.366% |
| Mobile Lads Corp. | -2.24 Million USD | 98.885% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -104.432% |
| Qrons Inc. | -40.08 Thousand USD | 37.626% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 94.853% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 104.74% |
| Rebus Holdings, Inc. | -951 Thousand USD | 97.371% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 97.646% |
| International Stem Cell Corporation | 202 Thousand USD | 112.376% |
| Bioxytran, Inc. | -3.82 Million USD | 99.346% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 52.508% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 98.985% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.93% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | 44.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 99.087% |
| Neutra Corp. | -181.24 Thousand USD | 86.207% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.876% |
| PureTech Health plc | -11.62 Million USD | 99.785% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.876% |
| IXICO plc | -707 Thousand USD | 96.464% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.675% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.948% |
| CSL Limited | 4.73 Billion USD | 100.001% |
| Cellectis S.A. | -92.63 Million USD | 99.973% |